Skip to main content
. 2018 Oct 20;35(11):1894–1904. doi: 10.1007/s12325-018-0799-5

Fig. 4.

Fig. 4

Adherence rates during 1-year follow-up for no-switch and switch patients among a patients stable on any IFN beta therapy* at baseline and b patients stable on IM IFN beta-1a therapy at baseline. IFN interferon, IM intramuscular, MPR medication possession ratio, PDC proportion of days covered, SC subcutaneous. *SC IFN beta-1a, SC IFN beta-1b, or IM IFN beta-1a